Denali Therapeutics Inc (FRA:4DN)
€ 20.31 -0.18 (-0.88%) Market Cap: 2.85 Bil Enterprise Value: 2.09 Bil PE Ratio: 0 PB Ratio: 2.25 GF Score: 54/100

Denali Therapeutics Inc at Goldman Sachs Healthcare Conference Transcript

Jun 13, 2023 / 10:20PM GMT
Release Date Price: €29.89 (+5.81%)
Salveen Jaswal Richter
Goldman Sachs Group, Inc., Research Division - VP

Good afternoon. Thanks, everyone, for joining. Salveen Richter, biotechnology analyst at Goldman Sachs, and really pleased to have the Denali team with us. So with us, we have Ryan Watts, who's the CEO, Co-Founder and President; and Alexander Schuth, who is the COO and CFO and Co-Founder as well. Thank you both for joining us.

Questions & Answers

Salveen Jaswal Richter;Ryan J. Watts
Goldman Sachs Group, Inc., Research Division - VP;Denali Therapeutics Inc.

To start here, maybe just an outlook question on the company. You've made steady progress with your pipeline here, notably with the positive data that we've seen from the blood-brain barrier with that first data in Hunter's syndrome. And then we've also seen Biogen opt-in recently to the ATV data program. So as we look to the second half of the year, what do you see as the most important steps to further advance these different verticals and programs? And where should investors be most focused?

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot